We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||94.50 x 900|
|Ask||117.00 x 800|
|Day's Range||113.75 - 114.73|
|52 Week Range||90.10 - 116.49|
|PE Ratio (TTM)||20.32|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.00 (1.81%)|
|1y Target Est||116.13|
Physicians and health plan executives agreed healthcare has made little progress toward value-based care since last year – more than two-thirds (67 percent) of physicians and health plan executives said the U.S. still has a fee-for-service system. Fifty-seven percent of health plan executives said they now believe physicians do not have the tools to succeed under value-based care, up significantly from 45 percent in last year's study.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting DGX. Over the last one-month, outflows of investor capital in ETFs holding DGX totaled $1.29 billion.
Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.
SECAUCUS, N.J. , July 11, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting DGX. Over the last one-month, outflows of investor capital in ETFs holding DGX totaled $2.83 billion.
NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coca-Cola ...
It's part of a broader $350 million fund to prevent and treat Alzheimer's.
Two American lab companies, Quest Diagnostics and Clinical Pathology Laboratories, have processed cervical cancer screenings for women in Ireland. But a government review in 2014 found the labs mistakenly cleared more than 200 women there who were later diagnosed with cervical cancer. CBS News' Roxana Saberi spoke with two women who received settlements.
|Upgrade||Evercore ISI Group: In-Line to Outperform||7/10/2018|
|Downgrade||Deutsche Bank: Buy to Hold||6/27/2018|
|Upgrade||Barclays: Equal-Weight to Overweight||6/25/2018|
|Upgrade||William Blair: Market Perform to Outperform||6/8/2018|
|Upgrade||Morgan Stanley: Equal-Weight to Overweight||5/29/2018|
|Upgrade||Morgan Stanley: Underweight to Equal-Weight||3/14/2018|
Industry: Diagnostics & Research
Full Time Employees: 45,000
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.